TD Cowen Insights
Conversation with Welldoc
Jun 22, 2020
In this episode, Anand Iyer, Chief Strategy Officer of Welldoc, discusses the development and outcomes of Welldoc's BlueStar, a mobile prescription therapy for type 2 diabetes. They explore the potential for reversing diabetes, improving diabetes care through technology and data analysis, and the challenges of commercializing digital therapeutics. They also touch on the opportunities for improving healthcare through digital tools and data insights.
41:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- WellDoc's digital therapeutic, BlueStar, has shown significant improvements in A1C levels for patients with type 2 diabetes, exceeding FDA requirements for new drug clearance.
- Commercializing digital therapeutics requires overcoming challenges such as establishing a viable business model, educating healthcare providers, and adapting to regulatory and payment barriers.
Deep dives
Overview of WellDoc and its Digital Therapeutics
WellDoc is a digital health and digital therapies company that uses automated AI-driven digital software to support patients and healthcare providers in managing chronic conditions. They provide real-time coaching and feedback to patients based on their input of various parameters like glucose levels, medication, and lifestyle choices. WellDoc also offers clinical decision support for healthcare providers, analyzing patient data and providing insights and recommendations. The use of WellDoc's digital therapeutics has shown significant improvements in hemoglobin A1C levels, reduced healthcare costs, and increased engagement from both providers and patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
